Infinity cuts 20% of workforce as it refocuses on PI3K and retaspimycin
This article was originally published in Scrip
Infinity Pharmaceuticals revealed in its second quarter 2012 financial report that it cut 20% of its workforce - 40 employees at the company's Cambridge, Massachusetts headquarters - after shutting down its Hedgehog pathway programme and renegotiating its partnership with Mundipharma International.
You may also be interested in...
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Revenue declined in 2022 but the company expects it to increase 2% this year, offsetting an anticipated $3.5bn drop in Revlimid sales as new launches generate $4bn in 2023.